GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (FRA:HBP0) » Definitions » EPS without NRI

Helix BioPharma (FRA:HBP0) EPS without NRI : €-0.15 (TTM As of Jul. 2024)


View and export this data going back to . Start your Free Trial

What is Helix BioPharma EPS without NRI?

Helix BioPharma's earnings per share without non-recurring items for the three months ended in Jul. 2024 was €-0.07. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jul. 2024 was €-0.15.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Helix BioPharma's EPS without NRI or its related term are showing as below:

FRA:HBP0' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.9   Med: 7.8   Max: 19.9
Current: -43.9

FRA:HBP0's 3-Year EPS without NRI Growth Rate is ranked worse than
88.15% of 1241 companies
in the Biotechnology industry
Industry Median: 4.6 vs FRA:HBP0: -43.90

Helix BioPharma's EPS (Diluted) for the three months ended in Jul. 2024 was €-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 was €-0.15.

Helix BioPharma's EPS (Basic) for the three months ended in Jul. 2024 was €-0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jul. 2024 was €-0.15.


Helix BioPharma EPS without NRI Historical Data

The historical data trend for Helix BioPharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma EPS without NRI Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 - - -0.55 -0.70

Helix BioPharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.02 -0.03 -0.07

Competitive Comparison of Helix BioPharma's EPS without NRI

For the Biotechnology subindustry, Helix BioPharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's PE Ratio without NRI falls into.



Helix BioPharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helix BioPharma  (FRA:HBP0) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Helix BioPharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.

Helix BioPharma Headlines

No Headlines